Neoadjuvant gemcitabine and carboplatin followed by immediate cystectomy may be associated with a survival benefit in patients with clinical T2 bladder cancer

Neoadjuvant cisplatin-based chemotherapy for muscle-invasive bladder cancer (MIBC) is more beneficial for clinical T3/4 than clinical T2 (cT2) disease. The aim of this study was to assess whether neoadjuvant GCarbo has a survival impact on cT2 bladder cancer. We retrospectively reviewed the medical...

Descripción completa

Detalles Bibliográficos
Autores principales: Koie, Takuya, Ohyama, Chikara, Yamamoto, Hayato, Imai, Atsushi, Hatakeyama, Shingo, Yoneyama, Takahiro, Hashimoto, Yasuhiro, Yoneyama, Tohru, Tobisawa, Yuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2014
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006118/
https://www.ncbi.nlm.nih.gov/pubmed/24700028
http://dx.doi.org/10.1007/s12032-014-0949-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006118/
https://www.ncbi.nlm.nih.gov/pubmed/24700028
http://dx.doi.org/10.1007/s12032-014-0949-9

Ejemplares similares